Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 4/20 | 0.50 |
| ▸ | CCR1 | P32246 | 4/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577347 | 0.87 | GAA (0.46) | CXCR3MCHR1SCN2ASCN10AMEN1 | |
| SCHEMBL5577730 | 0.86 | CCR1 (0.48) | CXCR3CCR1MCHR1HTR2CMEN1 | |
| SCHEMBL5577376 | 0.85 | MAPK8 (0.43) | CXCR3CCR1MCHR1HTR2CMEN1 | |
| SCHEMBL5577645 | 0.85 | SCN10A (0.54) | CXCR3MCHR1HTR2CSCN2ASCN10A | |
| SCHEMBL5577303 | 0.84 | CCR1 (0.50) | CXCR3CCR1MCHR1MEN1KMT2A | |
| SCHEMBL5577584 | 0.83 | SCN10A (0.47) | CXCR3MCHR1HTR2CSCN2ASCN10A | |
| SCHEMBL5577690 | 0.82 | CXCR3 (0.58) | CXCR3CCR1MEN1KMT2A | |
| SCHEMBL5577684 | 0.82 | CXCR3 (0.51) | CXCR3CCR1MEN1KMT2A | |
| SCHEMBL5577844 | 0.82 | SCN10A (0.56) | CXCR3MCHR1HTR2CSCN2ASCN10A | |
| SCHEMBL5577641 | 0.81 | MCHR1 (0.51) | MCHR1HTR2CMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | CXCR3 32/4885CCR1 103/4885MCHR1 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.